共查询到20条相似文献,搜索用时 15 毫秒
1.
[目的]探讨腹水超滤浓缩回输腹腔术对肝硬化顽固性大量腹水患者并发Ⅱ型肝肾综合征的疗效。[方法]将66例肝硬化顽固性大量腹水同时并发Ⅱ型肝肾综合征的患者随机分为治疗组(34例)和对照组(32例);治疗组采用腹水超滤浓缩回输腹腔术治疗,对照组采用腹腔穿刺放液治疗。[结果]2组治疗后,在改善24h尿量、降低血清尿素氮、降低血清K+方面均较治疗前有效,但治疗组明显优于对照组(P0.05);2组不良反应发生率比较差异无统计学意义(P0.05)。[结论]合理应用腹水超滤浓缩回输腹腔术是一种治疗肝硬化顽固性大量腹水并发Ⅱ肝肾综合征的有效措施,可迅速改善患者肾脏功能,明显增加尿量,缓解氮质血症,解除高钾血症。 相似文献
2.
术前穿刺置管持续腹水引流对肝硬化伴顽固性腹水患者肝移植效果的影响 总被引:1,自引:0,他引:1
目的 评价术前穿刺置管持续腹水引流对拟行肝移植的肝硬化伴顽固性腹水患者肝移植效果的影响.方法 将2003年2月-2005年12月在我院行肝移植术的肝硬化伴顽固性腹水患者随机分为对照组(单纯药物治疗)和实验组(术前加穿刺置管腹水引流),分析治疗效果,并对肝移植疗效(包括随访)进行比较.结果 实验组穿刺置管腹水引流操作中无并发症发生,治疗后症状缓解率明显高于对照组,体重降低,尿量增加,尿蛋白降低,移植后半年血肌酐明显低于治疗前.对照组治疗后较治疗前MELD评分分值显著性升高.结论 术前穿刺置管持续腹水引流技术安全稳定,相比单纯药物治疗,综合治疗能够提高肝硬化伴顽固性腹水患者的术前状况. 相似文献
3.
Francesco Salerno Monica Guevara Mauro Bernardi Richard Moreau Florence Wong Paolo Angeli Guadalupe Garcia‐Tsao Samuel S. Lee 《Liver international》2010,30(7):937-947
Ascites is a frequent complication of cirrhosis and portal hypertension, because of the increase of the sinusoidal hydrostatic pressure. Cirrhosis accounts for over 75% of episodes of ascites. Cirrhotic patients with ascites have marked alterations in the splanchnic and systemic haemodynamics, causing central hypovolaemia and arterial hypotension with consequent activation of the vasoconstrictor systems, renin–angiotensin and sympathetic systems, and with increased renal sodium re‐absorption. One of the most serious complications in cirrhotic patients with ascites is the occurrence of refractoriness, that is the inability to resolve ascites by the standard medical treatment with low sodium diet and diuretic doses up to 160 mg/day of furosemide and 400 mg/day of spironolactone. Many patients with refractory ascites also have a chronic renal insufficiency that is called hepatorenal syndrome type‐2. In these patients ascites may be treated with periodic paracentesis or with transjugular intrahepatic portosystemic shunt. However, only liver transplantation may improve the survival of such patients. 相似文献
4.
A. Berzigotti D. Magalotti C. Cocci L. Angeloni L. Pironi M. Zoli 《Digestive and liver disease》2006,38(2):138-142
Chylous ascites is a rare complication of liver cirrhosis associated with a poor short-term prognosis. We report the case of an 80-year-old male cirrhotic patient with refractory chylous ascites associated with portal hypertension. He was treated with total parenteral nutrition but chylous ascites relapsed at suspension. Patient was put on long-term subcutaneous octreotide (100 microg t.i.d.) as an outpatient. The treatment was well tolerated and led to clinical improvement, markedly reducing the need of total paracentesis and the amount of ascites. Octreotide was stopped after 6 months, and massive ascites did not relapse. After 1 year the patient was alive, with no need of paracentesis. Octreotide therapy should be considered in patients with cirrhosis and chylous ascites to simplify the outpatient management of the disease. 相似文献
5.
Evaluation and management of patients with refractory ascites 总被引:1,自引:0,他引:1
Some patients with ascites due to liver cirrhosis become no longer responsive to diuretics. Once other causes of ascites such as portal vein thrombosis, malignancy or infection and non-compliance with medications and low sodium diet have been excluded, the diagnosis of refractory ascites can be made based on strict criteria. Patients with refractory ascites have very poor prognosis and therefore referral for consideration for liver transplantation should be initiated. Search for reversible components of the underlying liver pathology should be undertaken and targeted therapy, when available, should be considered. Currently, serial large volume paracentesis (LVP) and transjugular intrahepatic portasystemic stent-shunt (TIPS) are the two mainstay treatment options for refractory ascites. Other treatment options are available but not widely used either because they carry high morlJidity and mortality (most surgical options) rates, or are new interventions that have shown promise but still need further evaluation. In this comprehensive review, we describe the evaluation and management of patients with refractory ascites from the prospective of the practicing physician. 相似文献
6.
目的 探讨腹水超滤浓缩回输腹腔术治疗肝硬化顽固性腹水的疗效。方法 将56例肝硬化顽固性腹水患者随机分为2组,均给予保肝、利尿及抗病毒治疗。在此基础上,对治疗组行腹水超滤浓缩回输腹腔术加小剂量人血白蛋白静脉滴注(静滴)(每滤出1000ml腹水,静滴人血白蛋白4g),对对照组行大量放腹水加大剂量人血白蛋白静滴(每抽出1000ml腹水,静滴人血白蛋白8g)。结果 术后第14天,治疗组患者24h尿量、血清ALB水平均高于对照组(P均<0.05),且治疗组总有效率高于对照组(P<0.05)。结论 腹水超滤浓缩回输腹腔术是一种安全有效的治疗肝硬化顽固性腹水的方法。 相似文献
7.
Hitoshi Yoshiji 《Hepatology research》2023,53(9):794-805
Liver cirrhosis is a severe illness, associated with multiple complications, which can lead to liver failure. One of the major complications of cirrhosis is ascites. This review describes a stepped treatment approach for the management of ascites in Japanese patients with cirrhosis. It is broadly based on the 2020 update of the Japanese clinical practice guidelines for liver cirrhosis, which is briefly compared with guidelines from Europe and the United States. Step 1 is sodium restriction at a level suitable for Japanese individuals (5–7 g/day), Step 2 is albumin treatment to counteract underlying hypoalbuminemia, Step 3 is initiation of diuretic treatment with spironolactone, followed by add-on loop diuretic treatment at Step 4. Patients that are refractory to sodium restriction and sodium diuretics can be treated with tolvaptan (Step 5) – a vasopressin V2 receptor antagonist that is available in Japan. Patients at Steps 6 and 7 have refractory ascites and are treated with large volume paracentesis in combination with an albumin infusion. High-dose albumin infusion (6–8 g/L) at the time of large volume paracentesis has recently become possible in Japan. Cell-free and concentrated ascites reinfusion therapy is also an option at Step 6. Two of the treatment options at Step 7 are limited in Japan (transjugular intrahepatic portosystemic shunts are not approved, and access to liver donors is very limited), but patients can undergo a peritoneovenous shunt if no other options are available. While challenges remain in the treatment of ascites, adopting this stepwise treatment approach may improve patient outcomes. 相似文献
8.
Delphine Weil-Verhoeven Vincent Di Martino Guido Stirnimann Jean Paul Cervoni Eric Nguyen-Khac Thierry Th venot 《World journal of hepatology》2022,14(7):1344-1356
Refractory ascites (RA) is a frequent and life-threatening complication of cirrhosis. In selected patients with RA, transjugular intrahepatic portosystemic shunt (TIPS) placement and liver transplantation (LT) are currently considered the best therapeutic alternatives to repeated large volume paracentesis. In patients with a contraindication to TIPS or LT, the alfapump® system (Sequana Medical, Ghent, Belgium) has been developed to reduce the need for iterative paracentesis, and consequently to improve the quality of life and nutritional status. We report here recent data on technical progress made since the first implantation, the efficacy and tolerance of the device, the position of the pump in the therapeutic arsenal for refractory ascites, and the grey areas that remain to be clarified regarding the optimal selection of patients who are potential candidates for this treatment. 相似文献
9.
腹水超滤浓缩回输腹腔治疗肝硬化顽固性腹水疗效评价 总被引:1,自引:0,他引:1
目的 评估腹水超滤浓缩回输腹腔术治疗肝炎肝硬化顽固性腹水患者临床疗效。方法75例肝硬化顽固性腹水患者分为治疗组(50例)和对照组(25例),两组患者均采用保肝、利尿、对症、支持等常规治疗,疗程4周。对照组在常规治疗基础上,采用多次治疗性腹穿放液治疗;治疗组在常规治疗基础上,采用腹水超滤浓缩回输腹腔治疗,观察并比较两组治疗后体重、腹围、24h尿量和尿钠排出量、肝功能、肾功能、血电解质及不良反应。结果治疗4周后治疗组腹围、体重、24h尿量优于对照组(P〈0.01);血清白蛋白、肾小球滤过率及24h尿钠量高于对照组(P〈0.01),肌酐、胱抑素c水平低于对照组(P〈0.05。P〈0.01);治疗组显效率(48.0%)和总有效率(80.0%)明显好于对照组(24.0%和52.0%)(P〈0.05):两组均未出现严重不良反应。结论腹水超滤浓缩回输腹腔术治疗肝硬化顽固性腹水患者临床疗效优于多次治疗性腹穿放液。 相似文献
10.
Hideki Ijichi Yuji Soejima Akinobu Taketomi Tomoharu Yoshizumi Hideaki Uchiyama Noboru Harada Yusuke Yonemura Yoshihiko Maehara 《Liver international》2008,28(1):143-145
Chylous ascites is a rare complication following liver transplantation. A variety of treatment options have been proposed for the management of chylous ascites; however, their effectiveness following a liver transplant is unknown. A 40‐year‐old woman who underwent living donor liver transplantation for primary biliary cirrhosis developed chylous ascites 21 days after the transplant. A conventional treatment consisting of a low‐fat diet with total parenteral nutrition failed to treat the complication for 104 days. However, the use of somatostatin in combination with total parenteral nutrition resulted in a rapid falloff in chyle output without any adverse effects. Somatostatin and total parenteral nutrition are an effective option for the treatment of chylous ascites after living donor liver transplantation. 相似文献
11.
Agnete Nordheim Riedel Nina Kimer Lise Hobolth Lise Lotte Gluud 《Scandinavian journal of gastroenterology》2018,53(3):340-344
Objective: To evaluate the safety of PleurX in cirrhotic patients with refractory ascites.Methods: We prospectively registered patients who received a PleurX catheter cirrhosis-associated refractory ascites at our department from July 2015 to November 2016. Our control group consisted of matched cirrhotic patients with refractory ascites treated with large volume paracentesis (LVP) and patients with malignant ascites treated with PleurX during the same period.Results: We included 25 patients with cirrhosis-related ascites (7 in PleurX group) and 17 with malignant ascites (14 in PleurX group). Of these, six patients had hepatocellular carcinoma and cirrhosis (5 in PleurX group). None were eligible for insertion of a TIPS or liver transplantation. The maximum duration of follow-up was (480 days) in the PleurX group and 366 days in the LVP group (median 84 and 173 days, respectively). There was no difference in mortality when comparing PleurX with LVP treatment (hazard ratios: 3.0 and 1.0, p?=?.23 and .96, respectively). Mortality was higher in patients with malignant ascites (p=?.01). We found no significant differences in adverse events (incl. spontaneous bacterial peritonitis) or in P-albumin, P-creatinine and P-sodium between the groups.Conclusion: PleurX insertion for the treatment of refractory ascites in cirrhotic patients appears to be safe. Prospective randomized trials are necessary in order to confirm these findings. 相似文献
12.
Although, total paracentesis associated with human albumin substitution has shown to be a rapid, effective and safe treatment of diuretic refractory ascites in advanced liver cirrhosis, it implies high costs and has a limited availability. Therefore an alternative procedure the reinfusion of concentrated ascites has gained popularity in recent years (Smart et al. 1990; Grazioto et al. 1997). It was the aim of the study to compare human albumin substitution vs. reinfusion of ascitic-ultrafiltrate after total paracentesis. 35 patients with cirrhosis and tense ascites received total paracentesis associated with either human albumin (5-8 g/l ascites) (= group A) or reinfusion of an ascitic-ultrafiltrate fluid by means of hemofiltration technique (= group B). The mean volume of ascites removed was 9.41 (2.1-20.0) in group A and 11.41 (6.5-21.0) in group B. No significant differences in serum electrolytes, liver and renal function, coagulation profiles and hormones of the renin-angiotensin-aldosterone system were observed during hospitalization. In both groups sodium excretion increased significantly. 43% of the patients in group B developed pyrexia and chill after reinfusion of the ascitic-ultrafiltrate fluid. In one patient an anaphylactic bronchospasm occurred requiring IUC-treatment. The treatment cost in case of human albumin were 326.-DM vs. 290.-DM for each patient treated with ascitic-ultrafiltrate fluid reinfusion. The probabilities of hospital readmission and survival were similar in both groups during follow-up. The results indicate that i.v. infusion of ascitic-ultrafiltrate fluid is as effective as total paracentesis and albumin infusion in case of diuretic refractory ascites. However, according to the costs of instruments and staff and due to the significant allergic reactions caused by ascitic fluid it cannot be considered as a real alternative to albumin substitution. 相似文献
13.
Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis 总被引:13,自引:0,他引:13
Ginès P Uriz J Calahorra B Garcia-Tsao G Kamath PS Del Arbol LR Planas R Bosch J Arroyo V Rodés J 《Gastroenterology》2002,123(6):1839-1847
BACKGROUND & AIMS: The transjugular intrahepatic portosystemic shunt (TIPS) has been shown to be more effective than repeated paracentesis plus albumin in the control of refractory ascites. However, its effect on survival and healthcare costs is still uncertain. METHODS: Seventy patients with cirrhosis and refractory ascites were randomly assigned to TIPS (35 patients) or repeated paracentesis plus intravenous albumin (35 patients). The primary endpoint was survival without liver transplantation. Secondary endpoints were complications of cirrhosis and costs. RESULTS: Twenty patients treated with TIPS and 18 treated with paracentesis died during the study period, whereas 7 patients in each group underwent liver transplantation (mean follow-up 282 +/- 43 vs. 325 +/- 61 days, respectively). The probability of survival without liver transplantation was 41% at 1 year and 26% at 2 years in the TIPS group, as compared with 35% and 30% in the paracentesis group (P = 0.51). In a multivariate analysis, only baseline blood urea nitrogen levels and Child-Pugh score were independently associated with survival. Recurrence of ascites and development of hepatorenal syndrome were lower in the TIPS group compared with the paracentesis group, whereas the frequency of severe hepatic encephalopathy was greater in the TIPS group. The calculated costs were higher in the TIPS group than in the paracentesis group. CONCLUSIONS: In patients with refractory ascites, TIPS lowers the rate of ascites recurrence and the risk of developing hepatorenal syndrome. However, TIPS does not improve survival and is associated with an increased frequency of severe encephalopathy and higher costs compared with repeated paracentesis plus albumin. 相似文献
14.
Treatment of cirrhotic ascites 总被引:3,自引:0,他引:3
Cirrhosis is the most common cause of ascites and accounts for almost 85% of all cases. It is the most common complication of cirrhosis, after development of ascites only 50% of patients will survive for 2 to 5 years. Successful treatment is dependent on accurate diagnosis of the cause of ascites. Because sodium and water retention is the basic abnormality leading to ascites formation, restriction of sodium intake and enhancing sodium excretion is the mainstay of the treatment of ascites. Patients with cirrhosis and ascites must limit sodium intake to 2 gram per day. Enhancement of sodium excretion can be accomplished by usage of oral diuretics. The recommended initial dose is spironolactone 100-200 mg/d and furosemide 20-40 mg/d. usual maximum doses are 400 mg/d of spironolactone and 160 mg/d of furosemide. The recommended weight loss in patients without peripheral edema is 300 to 500 g/d. There is no limit to the daily weight loss of patients who have edema. About 90% of patients respond well to medical therapy for ascites. Refractory ascites is defined as fluid overload that is unresponsive to sodium restricted diet and high dose diuretic treatment (diuretic resistant) or when there is an inability to reach maximal dose of diuretics because of adverse effects (diuretic-intractable). It has a poor prognosis. Treatment options for patients with refractory ascites are serial therapeutic paracentesis, transjugular intrahepatic stent-shunt (TIPS) or peritoneovenous shunt and liver transplantation. TIPS should be considered in patients who repeatedly fail large-volume paracentesis and have relatively preserved liver functions. Liver transplantation is the only modality that is associated with improved survival. 相似文献
15.
Marika Rudler Maxime Mallet Philippe Sultanik Charlotte Bouzbib Dominique Thabut 《Liver international》2020,40(Z1):128-135
Ascites is the most common complication of cirrhosis, which develops in 5%‐10% of patients per year. Its management is based on symptomatic measures including restriction of sodium intake, diuretics and paracentesis. Underlying liver disease must always be treated and may improve ascites. In some patients, ascites is not controlled by medical therapies and has a major impact on quality of life and survival. TIPS placement and liver transplantation must therefore be discussed. More recently, repeated albumin infusions and Alfapump® have emerged as new therapies in ascites. In this review, the current data on these different options are analysed and an algorithm to help the physician make clinical decisions is suggested. 相似文献
16.
腹水是肝硬化最常见的并发症,并与发生感染、稀释性低钠血症、肾功能衰竭和病死率增加密切相关。无并发症的少量腹水患者早期处理原则是,休息加上低钠饮食。中等量腹水患者,一般选择低剂量利尿剂就能达到利尿效果。大量腹水患者,可大量放腹水+静点白蛋白(8g/每放腹水1000ml)。顽固性腹水患者,可用重复多次大量放腹水+血浆扩容治疗或用经颈静脉肝内门体分流术(TIPS)治疗。新药(如V2受拮抗剂和血管收缩剂等)对肝硬化腹水的治疗可能带来希望。 相似文献
17.
全腹腔穿刺放液对肝硬化门静脉血流动力学的影响 总被引:11,自引:2,他引:11
目的 观察全腹腔穿刺放液静脉输注生理盐水对肝硬化难治性腹水及门静脉血流动力学的影响。方法 将 1 996- 0 1~ 2 0 0 2 - 1 2安徽省明光市中医院肝硬化顽固性腹水患者1 42例 ,随机分为两组。A组 87例 ,予保护肝细胞 ,利尿剂及全腹腔穿刺放腹水 ,将腹水一次放尽 ,同时静脉输注生理盐水按放腹水 1L输生理盐水 1 70mL计。B组 5 5例 ,只给保护肝细胞及利尿剂治疗。结果 腹水总有效率A、B两组各为 67 8% ,2 3 6% ,P <0 0 1。门静脉系血管内径缩小 ,血流速度加快 ,血流量减少 ,门静脉压力下降也以A组明显。无不良反应。结论 全腹腔穿刺放液静脉输注生理盐水可降低门静脉压力 ,在治疗肝硬化顽固性腹水中是安全、有效的。 相似文献
18.
目的研究不同腹水超滤量对难治性腹水临床疗效及安全性的影响。方法将符合诊断标准的71例肝硬化难治性腹水病例随机分为对照组和治疗组,对照组单次超滤量3 000~8 000 ml,3~7 d后再次或多次行腹水超滤治疗,治疗组单次超滤量8000~16 000 ml,抽尽腹水,若抽取废液量为3 000~8 000 ml,则纳入对照组。观察治疗前后临床症状、腹围、尿量、体质量、并发症、平均住院日、住院费用;治疗前、后3 d、随访3个月末检测肝肾功能、电解质等,计算Child pugh积分、Meld积分。结果 (1)治疗组、对照组腹水超滤次数分别为(2.14±1.07)次、(3.57±1.42)次,废液总量分别为(26 347.22±13 477.40)ml、(21 180.00±9 137.73)ml,平均住院日分别为(21.37±3.40)d、(26.46±2.78)d,平均住院费用分别为(15 356.12±3 526.15)元、(18 737.35±4 671.23)元,两组腹水超滤次数、平均住院日、平均住院费用相比,差异有统计学意义(P0.05),废液总量相比,差异无统计学意义(P0.05);(2)两组总有效率分别为91.67%、65.71%,差异有统计学意义(P=0.004);(3)两组发生肝性脑病、上消化道出血、肝肾综合征、原发性肝癌、死亡以及其他(局部渗血)情况相比,差异无统计学意义(P0.05)。结论腹水超滤浓缩回输术治疗单次超滤量8 000~16 000 ml比3 000~8 000 ml能显著降低腹水超滤次数、缩短住院日、降低住院费用,更有效控制腹水增长,两组治疗安全性均好,但腹水超滤浓缩回输术治疗不能阻止疾病的进展。 相似文献
19.
目的 目的 探讨肝纤维化并顽固性腹水的综合治疗方法。 方法 方法 收集54例肝纤维化并顽固性腹水住院患者, 随机
分为实验组和对照组。实验组采用改良中心静脉导管腹腔内留置进行放液、 灌洗、 腔内药物注射, 并结合全身情况综合治
疗。对照组常规腹腔穿刺抽液。结果 结果 实验组总有效率82.1%, 对照组总有效率57.7%, 差异有统计学意义 (χ2
= 3.87,
P<0.05)。实验组住院天数、 腹穿次数、 腹水消退时间均少于对照组, 差异均有统计学意义 (P均<0.05)。结论 结论 改良中心
静脉导管腹腔留置治疗肝纤维化并顽固性腹水安全、 有效、 方便。 相似文献
20.
V Arroyo 《Acta gastro-enterologica Belgica》1990,53(2):249-255
Refractory ascites (or diuretic-resistant ascites), i.e. ascites that cannot be mobilized by medical treatment (low sodium diet and high doses of furosemide and spironolactone) is an infrequent phenomenon in cirrhosis. It usually occurs in patients with functional renal failure as a consequence of alteration in both pharmacokinetics and pharmacodynamics of diuretics. Peritoneovenous shunting, a procedure which improves systemic hemodynamics and renal function and suppresses the plasma levels of renin, aldosterone, norepinephrine and antidiuretic hormone in cirrhotics with ascites, has been proposed as the treatment of choice in patients with refractory ascites. Unfortunately it is associated to a high rate of severe complications and does not prolong the survival of these patients. Moreover, in approximately one third of the patients the shunt becomes occluded within the first year after operation. Recent studies have shown that repeated large volume paracentesis (4-64 per day until disappearance of ascites) or total paracentesis (complete mobilization of ascites in only one paracentesis session) associated to i.v. albumin infusion are an effective and safe therapy of ascites. At present, there is only one controlled trial comparing therapeutic paracentesis versus peritoneo-venous shunt in the management of patients with refractory ascites. In this study, there were no significant difference between both therapeutic groups with respect to survival. However, the incidence of readmission to hospital for the treatment of ascites was higher in the paracentesis group. Therefore, both procedures are valid therapeutic alternatives for that type of patients. Future studies are necessary to investigate if there are subsets of cirrhotics with refractory ascites in which one of these two types of treatment is especially indicated. 相似文献